6804-07-5
基本信息
喹肼脂
卡巴得
卡巴氧
卡巴多
卡巴多司
2(2-喹啉基-1,1-亚甲基)肼基甲酸甲酯
N,N’-二氧化甲基(2-喹喔啉基亚甲基)肼羧酸酯
2-(喹喔啉-2-亚甲基)肼-羧酸甲酯-N,N'-二氧化物
M31
MOD1
gs6244
Mecadox
CARBADO
p25beta
getroxel
fortigro
karbadox
物理化学性质
| 熔点 | 239-240°C |
| 沸点 | 405.47°C (rough estimate) |
| 密度 | 1.3602 (rough estimate) |
| 折射率 | 1.6000 (estimate) |
| 闪点 | 18°(64°F) |
| 储存条件 | 2-8°C |
| 溶解度 | DMSO（轻微超声处理） |
| 酸度系数(pKa) | 10.51±0.46(Predicted) |
| 形态 | 粉末 |
| 颜色 | 黄色至深黄色 |
| 水溶解性 | Soluble in 1N NaOH (50 mg/ml), and water (partly). |
| 稳定性 | 感光 |
| CAS 数据库 | 6804-07-5 |
| EPA化学物质信息 | Hydrazinecarboxylic acid, 2-[(1,4-dioxido-2-quinoxalinyl)methylene]-, methyl ester (6804-07-5) |
安全数据
| 危险性符号(GHS) |    GHS02,GHS07,GHS08 |
| 警示词 | 危险 |
| 危险性描述 | H228-H302-H350 |
| 防范说明 | P201-P210-P240-P280-P405-P501a |
| 危险品标志 | F,T |
| 危险类别码 | 45-11-22 |
| 安全说明 | 53-45 |
| 危险品运输编号 | UN 1325 4.1/PG 2 |
| WGK Germany | 3 |
| RTECS号 | FE2779000 |
| 危险等级 | 4.1 |
| 海关编码 | 29339900 |
| 毒害物质数据 | 6804-07-5(Hazardous Substances Data) |
应用领域
卡巴多价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/01/25 | HY-B1340 | 卡巴多 Carbadox | 6804-07-5 | 100mg | 400元 |
| 2024/01/25 | HY-B1340 | 卡巴多 Carbadox | 6804-07-5 | 10mM * 1mLin DMSO | 440元 |
常见问题列表
Bacterial
The results of MTT assay demonstrate a dose-dependent decrease in mitochondrial activity in Vero cells at all concentrations of Carbadox. Treatment with Carbadox at the highest concentration of 160 μg/mL results in cell viability down to only 12%. Cells following Carbadox treatment show a dose-dependent increase of the DNA migration (p<0.01). The nuclear division index (NDI) reduces markedly with the increase doses of Carbadox.
Alpha diversities (Shannon diversity, Heips evenness, and inverse Simpson indices) of samples from medicated piglets compare to non-medicated piglets are significantly different at 2, 3, and 4 days after continuous Carbadox, but not different in either late Carbadox or at any time during the withdrawal period. Analysis of the community structure of bacteria in animals shows significant differences at days 3 and 4 of early Carbadox treatment ([R=0.32, p=0.015] and [R=0.54, p=0.003], respectively), but not before starting antibiotic treatment (p=0.82). No significant differences in E. coli colony forming units (CFUs) are observed during the Carbadox-treatment period of the study or late in the withdrawal period. E. coli CFUs are significantly different between the medicated and non-medicated groups on day 2 after the withdrawal of Carbadox.